233 related articles for article (PubMed ID: 33674246)
41. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
[TBL] [Abstract][Full Text] [Related]
42. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
[TBL] [Abstract][Full Text] [Related]
43. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
44. Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy.
Gupta A; Roy AM
Clin Genitourin Cancer; 2024 Aug; 22(4):102104. PubMed ID: 38834500
[TBL] [Abstract][Full Text] [Related]
45. Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis.
Yanagisawa T; Quhal F; Kawada T; Bekku K; Laukhtina E; Rajwa P; Deimling MV; Chlosta M; Pradere B; Karakiewicz PI; Mori K; Kimura T; Schmidinger M; Shariat SF
Immunotherapy; 2023 Oct; 15(15):1309-1322. PubMed ID: 37694583
[TBL] [Abstract][Full Text] [Related]
46. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
[No Abstract] [Full Text] [Related]
47. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
Jo H; Hong J; Kim H; Kim HR; Kwon GY; Kang KA; Park SY; Kim CK; Park BK; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH
Front Oncol; 2022; 12():874385. PubMed ID: 35574412
[TBL] [Abstract][Full Text] [Related]
48. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
49. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
50. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
[TBL] [Abstract][Full Text] [Related]
51. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Kissick HT; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Front Oncol; 2021; 11():707050. PubMed ID: 34307176
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
[TBL] [Abstract][Full Text] [Related]
53. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
54. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
55. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
[TBL] [Abstract][Full Text] [Related]
56. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
58. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
[TBL] [Abstract][Full Text] [Related]
59. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
[TBL] [Abstract][Full Text] [Related]
60. Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis.
Satkunasivam R; Guzman JC; Klaassen Z; Hall ME; Luckenbaugh AN; Lim K; Laviana AA; DeRosa AP; Beckermann KE; Rini B; Wallis CJ
Urol Oncol; 2022 Feb; 40(2):64.e17-64.e24. PubMed ID: 34690032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
